Want to see JP:4538 full AI Analyst Report?
4538 Stock Chart & Stats
¥2315.00
-¥64.00(-2.54%)
At close: 4:00 PM EST
¥2315.00
-¥64.00(-2.54%)
Day’s Range― - ―
52-Week Range¥1,990.00 - ¥2,530.00
Previous CloseN/A
Volume28.90K
Average Volume (3M)17.49K
Market Cap
¥19.04B
Enterprise Value¥41.13B
Total Cash (Recent Filing)¥4.85B
Total Debt (Recent Filing)¥28.46B
Price to Earnings (P/E)9.3
Beta0.60
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)235.54
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.58
Price to Sales (P/S)0.32
P/FCF Ratio-2.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Injectable FocusA clear specialization in injectables and infusion therapies indicates deep manufacturing know‑how, regulatory expertise and high barriers to entry in hospital channels. This niche focus supports stable institutional demand, long product life cycles and repeat hospital contracts over months to years.
Consistent Revenue GrowthSteady top‑line growth, including an acceleration in FY2026, signals durable market demand and product traction in its core hospital segments. Persistent revenue expansion underpins capacity utilization and long‑term cash generation potential if margins and working capital are managed.
Return To Modest ProfitabilityA recovery to positive net income in FY2026 shows operational resilience and that management actions can restore profitability. If maintained, this transition improves the company's ability to service debt, fund reinvestment, and rebuild cash buffers over the medium term.
Bears Say
Deteriorated Cash GenerationA sustained swing to negative operating and free cash flow in FY2025–FY2026 materially weakens financial resilience. Negative cash conversion constrains capex and working capital funding, raises refinancing needs and makes the business more vulnerable to profit or demand shocks.
Rising LeverageMaterial increase in debt‑to‑equity reduces balance‑sheet flexibility and raises interest and refinancing risk. With elevated leverage alongside weak cash flow, the company has less buffer to absorb margin pressure or fund R&D, increasing structural financial vulnerability over the medium term.
Margin And Profit VolatilityDeclining gross and EBITDA margins and swings between loss and small profit indicate structural cost pressure or pricing limits. Margin instability undermines sustainable free cash flow, complicates planning for R&D and capital expenditure, and increases execution risk over coming quarters.
Fuso Pharmaceutical Industries,Ltd. News
4538 FAQ
What was Fuso Pharmaceutical Industries,Ltd.’s price range in the past 12 months?
Fuso Pharmaceutical Industries,Ltd. lowest stock price was ¥1990.00 and its highest was ¥2530.00 in the past 12 months.
What is Fuso Pharmaceutical Industries,Ltd.’s market cap?
Fuso Pharmaceutical Industries,Ltd.’s market cap is ¥19.04B.
When is Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date?
Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 23 days.
How were Fuso Pharmaceutical Industries,Ltd.’s earnings last quarter?
Fuso Pharmaceutical Industries,Ltd. released its earnings results on May 12, 2026. The company reported ¥38.39 earnings per share for the quarter, beating the consensus estimate of N/A by ¥38.39.
Is Fuso Pharmaceutical Industries,Ltd. overvalued?
According to Wall Street analysts Fuso Pharmaceutical Industries,Ltd.’s price is currently Overvalued.
Does Fuso Pharmaceutical Industries,Ltd. pay dividends?
Fuso Pharmaceutical Industries,Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 3.71%. See more information on Fuso Pharmaceutical Industries,Ltd. dividends here
What is Fuso Pharmaceutical Industries,Ltd.’s EPS estimate?
Fuso Pharmaceutical Industries,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuso Pharmaceutical Industries,Ltd. have?
Fuso Pharmaceutical Industries,Ltd. has 9,451,169 shares outstanding.
What happened to Fuso Pharmaceutical Industries,Ltd.’s price movement after its last earnings report?
Fuso Pharmaceutical Industries,Ltd. reported an EPS of ¥38.39 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.227%.
Which hedge fund is a major shareholder of Fuso Pharmaceutical Industries,Ltd.?
Currently, no hedge funds are holding shares in JP:4538
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―